Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
617.00K | 636.00K | 510.00K | 154.00K | 341.00K | 456.00K | Gross Profit |
-7.49M | 289.00K | 266.00K | 116.00K | -557.00K | -166.00K | EBIT |
-12.43M | -12.89M | -11.03M | -8.60M | -7.51M | -4.95M | EBITDA |
-9.32M | -10.27M | -9.84M | -6.16M | -6.43M | -4.42M | Net Income Common Stockholders |
-11.11M | -11.57M | -10.83M | -6.71M | -6.68M | -4.31M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.19M | 2.83M | 5.25M | 999.00K | 4.34M | 11.51M | Total Assets |
11.07M | 12.11M | 16.13M | 11.34M | 15.38M | 15.35M | Total Debt |
6.00M | 5.74M | 6.44M | 6.14M | 6.59M | 541.00K | Net Debt |
4.82M | 3.91M | 1.19M | 5.16M | 4.41M | -5.58M | Total Liabilities |
9.44M | 7.75M | 10.07M | 8.76M | 8.69M | 1.77M | Stockholders Equity |
1.62M | 4.36M | 6.05M | 2.59M | 6.68M | 13.56M |
Cash Flow | Free Cash Flow | ||||
-7.46M | -10.77M | -9.01M | -6.08M | -9.01M | -3.86M | Operating Cash Flow |
-6.71M | -10.17M | -8.29M | -5.18M | -5.92M | -3.40M | Investing Cash Flow |
1.68M | -1.49M | -691.00K | 1.25M | 2.83M | 4.58M | Financing Cash Flow |
5.03M | 8.25M | 13.42M | 2.56M | -804.00K | -181.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | £10.43M | ― | -13.85% | ― | 7.27% | 39.64% | |
59 Neutral | £16.42M | ― | -137.62% | ― | 10.50% | -9.60% | |
54 Neutral | £6.87M | ― | -99.43% | ― | 17.39% | 96.02% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
50 Neutral | £7.83M | ― | -222.16% | ― | 24.71% | 38.28% | |
44 Neutral | £7.56M | ― | -129.49% | ― | 14.12% | 78.16% |
Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.
Oxford BioDynamics announced that Non-Executive Director Peter Presland has purchased 3,398,553 ordinary shares, representing approximately 0.17% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s future prospects and could positively influence stakeholder perceptions and market positioning.
Oxford BioDynamics Plc announced a transaction involving its CFO, Paul Stockdale, who transferred 791,176 ordinary shares into his ISA through a sale and repurchase process. This transaction, conducted on the London Stock Exchange, leaves Stockdale with a beneficial interest in 3,077,919 shares, representing 0.16% of the company’s issued share capital. This move is part of routine financial management and does not indicate any significant change in company operations or strategy.
Oxford BioDynamics Plc announced the successful passing of all resolutions at its Annual General Meeting. This development underscores the company’s continued commitment to advancing precision medicine through its innovative diagnostic tests, potentially enhancing its market position and stakeholder confidence.
Oxford BioDynamics has announced the appointment of Peter Presland as a Non-Executive Director and Chair of the Audit Committee, succeeding Matthew Wakefield. Presland brings extensive experience in business management and corporate governance, which is expected to enhance the board’s independence and governance capabilities. This strategic board change is anticipated to positively impact the company’s operational and governance structure, potentially benefiting stakeholders by strengthening the company’s leadership and oversight.
Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. The transaction has led to a decrease in the total percentage of voting rights held by Spreadex LTD, which could impact the company’s influence on corporate decisions and its strategic positioning within the industry.
Oxford BioDynamics has expanded its partnership with Bupa UK insurance to include coverage for its EpiSwitch® PSE prostate cancer test. This strategic agreement enhances access to the PSE test for Bupa’s 3.9 million customers, particularly those with raised PSA levels but no high-risk factors or symptoms. The PSE test, known for its high accuracy and positive predictive value, aims to improve early prostate cancer diagnosis and reduce unnecessary procedures, aligning with Bupa’s commitment to advanced cancer care.